VIA Pharmaceuticals, Inc. (VIAP)
- Previous Close
0.0000 - Open
0.0000 - Bid --
- Ask --
- Day's Range
0.0000 - 0.0000 - 52 Week Range
0.0000 - 0.0001 - Volume
700 - Avg. Volume
700 - Market Cap (intraday)
20 - Beta (5Y Monthly) -0.89
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4710 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.00
VIA Pharmaceuticals, Inc., a development stage biotechnology company, focuses on the development of compounds for the treatment of cardiovascular and metabolic diseases. It is developing a pipeline of small molecule drugs that target the underlying causes of cardiovascular and metabolic diseases, including vascular inflammation, high cholesterol, high triglycerides, and insulin sensitization/diabetes. The company's drug development pipeline includes VIA-3196, a Phase-1 ready liver-directed thyroid hormone receptor (THR) beta agonist that targets dyslipidemia, such as high LDL cholesterol, high triglycerides, and elevated Lp(a); Diacylglycerol Acyl Transferase 1 (DGAT1) inhibitor, which is in pre-clinical development stage treatment of type 2 diabetes with upside potential in weight control and dyslipidemia; and VIA-2291, a 5-Lipoxygenase inhibitor that has completed third Phase 2 clinical trial for the treatment of atherosclerotic plaque, an underlying cause of heart attack, stroke, and other vascular diseases. VIA Pharmaceuticals, Inc. has two research, development, and commercialization agreements with Hoffman-LaRoche Inc. and Hoffman-LaRoche Ltd. for THR beta agonist; and multiple compounds from preclinical DGAT1 metabolic disorders program. The company was founded in 2004 and is headquartered in San Francisco, California.
6
Full Time Employees
December 31
Fiscal Year Ends
--
Sector
--
Industry
Related News
Performance Overview: VIAP
Trailing total returns as of 4/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VIAP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VIAP
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-241.90%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-9.6M
Diluted EPS (ttm)
-0.4710
Balance Sheet and Cash Flow
Total Cash (mrq)
84k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-3.62M
Research Analysis: VIAP
Company Insights: VIAP
VIAP does not have Company Insights